Compare REAL & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REAL | MNKD |
|---|---|---|
| Founded | 2011 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2019 | 2004 |
| Metric | REAL | MNKD |
|---|---|---|
| Price | $9.85 | $3.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $17.00 | $8.69 |
| AVG Volume (30 Days) | 2.8M | ★ 5.0M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.55 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $692,845,000.00 | $348,966,000.00 |
| Revenue This Year | $14.30 | $35.81 |
| Revenue Next Year | $10.15 | $11.89 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 15.38 | ★ 22.23 |
| 52 Week Low | $4.71 | $2.23 |
| 52 Week High | $17.39 | $6.51 |
| Indicator | REAL | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 49.61 | 62.97 |
| Support Level | $9.61 | $3.30 |
| Resistance Level | $9.94 | $3.94 |
| Average True Range (ATR) | 0.51 | 0.22 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 82.04 | 67.97 |
The RealReal Inc is an online marketplace for authenticated, resale luxury goods, providing an end-to-end service that unlocks supply and creates a trusted, curated marketplace for buyers globally. Since its inception, the company has cultivated a loyal and engaged consignor and buyer base through continuous investment in its technology platform, logistics infrastructure, brand and people. It offers a wide selection of authenticated, mainly pre-owned luxury goods bearing the brands of thousands of luxury and premium designers, including Cartier, Chanel, Christian Dior, Gucci, Hermes, Louis Vuitton and Rolex. The company offers products across women's fashion, men's fashion, jewelry, and watches, promoting the recirculation of luxury goods and contributing to a more sustainable world.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.